US · GILD
Gilead Sciences, Inc.
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Foster City, CA 94404
- Website
- gilead.com
Price · as of 2025-12-31
$131.65
Market cap 184.8B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $122.57 | -6.9% |
| Intrinsic Value(DCF) | $101.36 | -23.01% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $71.32 | -45.82% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $16.01 | $52.12 | $20.18 | $12.74 | $24.05 |
| 2012 | $31.56 | $54.83 | $18.02 | $14.00 | $39.78 |
| 2013 | $55.29 | $85.96 | $21.51 | $16.73 | $45.99 |
| 2014 | $69.20 | $175.10 | $2,503.21 | $49.12 | $993.98 |
| 2015 | $63.03 | $179.14 | $4,712.18 | $54.50 | $469.69 |
| 2016 | $49.05 | $136.97 | $1,163.70 | $36.14 | $16.40 |
| 2017 | $59.75 | $93.36 | $48.42 | $0.00 | $0.00 |
| 2018 | $48.29 | $67.52 | $16.06 | $0.00 | $0.00 |
| 2019 | $63.62 | $64.07 | $15.64 | $0.00 | $40.16 |
| 2020 | $50.81 | $51.69 | $10.94 | $0.00 | $1.73 |
| 2021 | $49.91 | $64.75 | $40.10 | $0.00 | $90.55 |
| 2022 | $71.54 | $66.26 | $17.87 | $0.00 | $29.75 |
| 2023 | $70.21 | $65.43 | $15.10 | $0.00 | $34.30 |
| 2024 | $114.22 | $74.17 | $10.59 | $0.00 | $5.34 |
| 2025 | $150.03 | $122.57 | $65.36 | $0.00 | $71.32 |
AI valuation
Our deep-learning model estimates Gilead Sciences, Inc.'s (GILD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $122.57
- Current price
- $131.65
- AI upside
- -6.9%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$101.36
-23.01% upside
Graham-Dodd
—
— upside
Graham Formula
$71.32
-45.82% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GILD | Gilead Sciences, Inc. | $131.65 | 184.8B | -7% | -23% | — | -46% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| BSX | Boston Scientific Corpora… | $76.85 | 114.04B | -12% | -35% | -82% | -31% | 39.02 | 4.66 | 5.62 | 33.01 | 70.68 | -105.55 | 69.01% | 19.78% | 14.38% | 12.57% | 10.11% | 6.96% | 0.51 | 11.38 | 1.62 | 0.91 | 2.78 | 5520.00% | 1987.00% | 3830.00% | 3.24% | 0.83 | 10.90% | 0.00% | 0.00% | 0.32% | 31.03 | 33.68 | 6.14 | 4.56 |
| DHR | Danaher Corporation | $210.64 | 148.95B | -10% | -58% | -90% | -73% | 40.32 | 2.77 | 5.93 | 22.97 | — | -17.28 | 60.93% | 20.91% | 14.71% | 7.08% | 6.70% | 4.49% | 0.35 | 19.38 | 1.87 | 1.25 | 1.99 | -473.00% | 290.00% | -68.00% | 3.61% | 0.94 | 8.03% | 0.60% | 24.30% | 3.59% | 31.05 | 30.32 | 6.49 | 4.20 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVO | Novo Nordisk A/S | $37.45 | 166.46B | +59% | +7% | — | -3% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| SYK | Stryker Corporation | $387.46 | 148.28B | -24% | -56% | — | -59% | 45.57 | 6.60 | 5.89 | 25.13 | 552.53 | -57.96 | 63.96% | 19.47% | 12.92% | 15.08% | 11.08% | 7.15% | 0.66 | 8.05 | 1.89 | 1.04 | 1.72 | 825.00% | 1116.00% | 2283.00% | 2.90% | 0.65 | 13.50% | 0.87% | 39.60% | 0.87% | 32.46 | 37.05 | 6.32 | 4.53 |
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
- CEO
- Johanna Mercier
- Employees
- 17.6K
- Beta
- 0.39
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($101.36 ÷ $131.65) − 1 = -23.01% (DCF, example).